Tempest Therapeutics Inc
Change company Symbol lookup
Select an option...
TPST Tempest Therapeutics Inc
PETV PetVivo Holdings Inc
KMI Kinder Morgan Inc
NXPL NextPlat Corp
D Dominion Energy Inc
CVS CVS Health Corp
CVI CVR Energy Inc
CTRE CareTrust REIT Inc
CSWC Capital Southwest Corp
CSCO Cisco Systems Inc

Health Care : Biotechnology |
Company profile

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Closing Price
Day's Change
-0.20 (-9.76%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Meta's pivot from 'irresponsible' metaverse spending earns stock an upgrade

9:50 am ET March 20, 2023 (MarketWatch)

By Emily Bary

Edward Jones analyst was previously worried about profligate spending on the metaverse but is now 'encouraged' by cost cuts

Meta Platforms Inc.'s stock recently secured an upgrade from a Wall Street analyst who applauded the company's increased discipline.

Edward Jones analyst David Heger upgraded Meta shares (META) to buy from hold late Friday, writing of his increased optimism in the company's earnings outlook due to expense reductions and the prospect for a stabilization in advertising revenue this year.

His upgrade comes after Meta announced last week that it planned to cut about 10,000 more jobs, building on the 11,000-plus layoffs disclosed last fall.

Read: Meta to cut 10,000 more jobs in latest round of layoffs for Facebook parent

"We had been concerned about the planned increase in expenses in 2023, much of which was earmarked for the company's metaverse initiative," he wrote. "We feltthat management was being irresponsible considering the weakened environment for ad spending."

More recently, however, the Facebook parent company has "announced efforts to reduce expenses, focus on efficiency and improve profitability," Heger noted. The company "has pulled back on its metaverse investment."

He added that he's "encouraged to see Meta reduce its cost structure to improve earnings during the uncertain macroeconomic environment."

See also:Meta contrasts with 'slow and lethargic pace' of its rivals as it cuts more jobs

Facebook parent Meta remains the "leader in social media" despite competitive challenges, Heger said, and the company's vast user base of 3.7 billion across its products should help it continue to provide useful analytics to marketers.

While the company faces pressure from antitrust regulators, Heger doesn't see a near-term threat from these developments. "We expect that these challenges will take years to resolve and do not impact user engagement or advertiser interest," he wrote.

Shares of Meta are up 1.3% in Monday morning trading. The stock has gained about 65% so far this year as the S&P 500 has risen 2%.

-Emily Bary

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

March 20, 2023 09:50 ET (13:50 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.